Crescent Star Insurance is a small, long-established Pakistani general insurer whose economics now turn on three linked questions: can its core underwriting return to profit, can its investment assets convert into dependable cash, and can the enlarged capital base support growth without reviving the regulatory problems that disrupted its guarantee business? The 2025 accounts show why these questions must be read together. Insurance premium contracted sharply and underwriting moved into loss, but investment and other income kept the company profitable.
Company Name: Crescent Star Insurance Ltd
Ticker: CSIL
This is an explanation of the business, not a recommendation to buy or sell its shares. Figures are identified as company-reported facts, management statements, contextual reporting or AlphaGen inference so that readers can separate evidence from interpretation.
What Crescent Star Insurance does
Reported fact: Crescent Star was incorporated in 1957 and is listed on the Pakistan Stock Exchange. It writes non-life insurance across fire and property, marine and transport, motor, accident and health, credit and suretyship, and miscellaneous classes. Its fiscal year ends in December. PSX company profile and company overview.
Unlike a manufacturer, CSIL does not transform raw materials into goods. Its operational inputs are risk capital, reinsurance capacity, underwriting judgment, distribution relationships, claims handling, technology, customer data and regulatory permissions. Premium is collected before all claims are known, creating insurance “float”; that float and shareholder capital are invested until claims and expenses are paid.
Products, customers and route to market
Six reporting portfolios
Fire and property protects physical assets against specified perils. Marine, aviation and transport covers goods moving through sea, air and land routes. Motor combines own-damage cover with third-party liability. Accident and health pays qualifying hospital and outpatient costs. Credit and suretyship includes guarantee-type exposures, while miscellaneous includes engineering, terrorism, personal accident, workers’ compensation, travel and crop cover. These descriptions come from the company’s published reporting and product pages. Official product and company information.
Management statement: Customer categories therefore range from individuals buying motor, health or travel policies to businesses protecting buildings, cargo, projects and contractual obligations. Distribution can be direct through the company’s staff and branches, through agents and intermediaries, and through institutions that place insurers on approved panels. Management says bank panel access and rating requirements constrain smaller insurers; that is a management view, not an independently established market-share conclusion.
Pricing and reinsurance
Premium pricing starts with the expected frequency and severity of claims, then adds acquisition cost, administrative expense, reinsurance cost, taxes and a margin for uncertainty. For catastrophe-prone property, marine cargo or large guarantees, the amount CSIL can safely retain is limited by its capital and by available reinsurance. Ceding risk reduces the premium retained but also limits loss severity. The economically relevant number is therefore not gross written premium alone: readers must compare earned and net premium, claims, commission, expense and the reinsurance position.
Key facts and figures
1. Established in 1957; the 2025 annual report was the company’s 69th annual report. FY2025 annual report.
2. The official website described CSIL as a registered non-life insurer, a PSX-listed company and a member of the Insurance Association of Pakistan, with paid-up capital of Rs1.077 billion before the 2026 rights completion. Company overview, updated May 22, 2026.
3. At December 31, 2025, unconsolidated total assets were Rs1.638 billion, up 7.6% from Rs1.523 billion a year earlier. FY2025 financial results.
4. Unconsolidated equity was Rs1.338 billion at December 31, 2025, up 5.4% from Rs1.269 billion. FY2025 financial results.
5. Gross premium was Rs79.29 million in 2025, almost flat against Rs79.73 million in 2024 but far below Rs359.26 million in 2023. Ten-year key financial highlights.
6. Net insurance premium was Rs97.79 million in 2025, down 56.4% from Rs224.37 million in 2024. Net premium can exceed the year’s gross writing when movements in unearned-premium reserves release premium written earlier. FY2025 financial results.
7. The underwriting result was a Rs49.46 million loss in 2025 versus a Rs65.76 million profit in 2024—a Rs115.22 million negative swing. FY2025 financial results.
8. Investment income rose to Rs68.17 million in 2025 from Rs29.49 million, while other income rose to Rs22.15 million from Rs4.86 million. FY2025 financial results.
9. Unconsolidated profit after tax was Rs20.94 million in 2025, down 76.0% from Rs87.16 million; basic and diluted EPS fell to Rs0.19 from Rs0.81. FY2025 financial results.
10. Investments were Rs474.88 million at December 31, 2025, up from Rs405.67 million, according to the annual report’s historical highlights. FY2025 annual report.
11. Operating cash flow was negative Rs51.64 million in 2025 versus negative Rs21.90 million in 2024; cash and bank balances fell to Rs2.69 million from Rs26.72 million. FY2025 financial results.
12. The March 31, 2026 quarter produced a net loss of about Rs39.46 million and loss per share of Rs0.27, compared with profit of Rs12.22 million and EPS of Rs0.11 a year earlier. Q1 2026 earnings release.
13. In March 2026 the company confirmed full subscription of 40,924,116 rights shares at Rs3 each, raising Rs122.77 million; PSX subsequently showed 148,619,157 shares outstanding. Rights subscription confirmation and PSX equity profile.
What the 2025 accounts reveal about the earnings engine
Reported fact: the insurance operation did not cover its own cost base in 2025. Net premium of Rs97.79 million was smaller than management expense of Rs143.49 million before considering acquisition costs and other underwriting items. The underwriting loss was therefore not caused by an unusually high reported claims burden—the net claims line was only Rs1.26 million—but by insufficient earned premium relative to the fixed operating platform and other underwriting charges.
AlphaGen inference: this is a scale-and-mix problem more than a simple loss-ratio problem. When premium volume contracts, salaries, branches, compliance, claims administration and systems do not fall at the same speed. A niche guarantee book can generate large fee or premium effects with low reported claims in good years, but concentration makes the income statement vulnerable if that class is interrupted. The 56% fall in net premium and the underwriting reversal illustrate that operating leverage.
Reported fact: investment income and other income together were Rs90.33 million in 2025, enough to offset the Rs49.46 million underwriting loss and support a Rs20.94 million after-tax profit. Investment income more than doubled, but profit still fell sharply. Readers should therefore avoid treating the 2025 bottom line as evidence that the core insurance franchise was healthy; the composition of profit matters more than the sign of profit.
Balance-sheet strength, cash conversion and the audit qualification
At December 31, 2025, underwriting provisions comprised Rs51.96 million of outstanding claims including IBNR, Rs13.47 million of unearned-premium reserve and Rs4.95 million of premium-deficiency reserve. Other creditors and accruals were Rs220.53 million. Those figures must be read alongside the Rs474.88 million investment pool and the very low Rs2.69 million cash balance. FY2025 results and annual report.
The most important caveat is the auditor’s qualified opinion. Reported fact: auditors said a Rs330.235 million accrued-interest receivable connected with an advance against shares in Dost Steels lacked documentary evidence supporting recoverability, and concluded that assets and solvency were overstated by that amount. They also cited Rs88.072 million of subsidiary investment and related advances without the impairment testing required by IAS 36, plus income-recognition issues on related loans. These are not minor presentation matters; they affect how much confidence readers should place in stated asset value, solvency and recurring earnings.
AlphaGen inference: subtracting the challenged Rs330.235 million from reported assets would not be a substitute for a formal impairment assessment, but its size—about 20% of FY2025 unconsolidated assets and about 25% of equity—shows why receivable quality is a first-order indicator. The exact accounting outcome depends on evidence, recoveries and auditor conclusions in future periods. Auditor’s qualified opinion.
The guarantee-business episode
Contextual reporting: in December 2024, SECP directed CSIL to cease guarantee business after saying the company had issued Rs229 billion of guarantees without required collateral or valid reinsurance. SECP also required monthly reporting of outstanding guarantees. Business Recorder report on the SECP action.
Contextual reporting: on July 31, 2025, CSIL told PSX that it had resumed guarantee business after the Islamabad High Court set aside and declared void the SECP directions. Business Recorder report on the resumption.
The two facts should be held together. The court outcome removed the specific cessation direction, but it does not make collateral, reinsurance or concentration risk economically irrelevant. Guarantee exposures can have low claims for long periods and then produce severe losses when a counterparty fails or collateral proves unavailable. Readers should monitor the current outstanding exposure, collateral coverage, reinsurance documentation and regulatory correspondence—not rely only on historical claim ratios or management’s characterization of the book.
Capital raise and growth options
The 38-for-100 rights offer added 40.924 million shares at Rs3 each and raised Rs122.77 million. The offer document said proceeds were intended for working capital, expansion, marketing and digitization of insurance products. The subscription was fully taken up by March 2026. Final rights offer document and subscription confirmation.
Economically, this capital can improve liquidity and give the insurer more room to write premium, but it also increases the number of shares across which future profit is divided. The test is not whether capital was raised; it is whether CSIL converts it into prudently priced, reinsured premium and operating cash without allowing management expense or weak receivables to absorb the benefit.
Subsidiaries and investment optionality
CSIL’s official investor page identifies Crescent Star Foods, Crescent Star Technologies and Crescent Star Luxury among associated companies. The FY2025 annual report said a proposed merger of Crescent Star Foods into PICIC Insurance remained before the Sindh High Court, and described plans to reposition Crescent Star Luxury as Crescent Star Ventures for corporate advisory work. Investor information and FY2025 annual report.
Subsequent contextual reporting said the renamed venture would seek the necessary approvals for advisory and consultancy activities. Separate reporting described an in-principle proposal involving Crescent Star Technologies and a digital-asset platform, also subject to approvals. These are proposals and strategic options, not established earnings streams. Venture rebranding report and digital-platform proposal.
AlphaGen inference: optionality should be valued only as execution becomes visible. Until approvals, capital commitments, ownership terms and audited contributions are clear, the subsidiaries are better treated as sources of complexity and impairment risk than as dependable profit drivers. The auditor’s untested-value qualification reinforces that discipline.
Competitive position and major dependencies
Structural strengths include a licence and operating history dating to 1957, a broad product menu, a nationwide branch claim, access to multiple underwriting classes and an enlarged share-capital base. The company’s own annual report states that its last insurer-financial-strength rating was A with Stable outlook on January 26, 2024, while the current rating was under review as of the 2025 governance statement. Readers should not assume the old rating remains current without a fresh agency release.
Its constraints are equally clear: small premium scale, dependence on a niche guarantee and transit franchise, high fixed expense relative to premium, qualification of material assets, thin cash at the 2025 year-end, and exposure to regulators, courts and reinsurance counterparties. Bank panel access and ratings can affect distribution. Political disruption to cross-border transit can reduce business. Inflation and rupee weakness raise claims severity; high interest rates can help portfolio yield but pressure customers and asset values; falling rates can do the reverse.
When the operating environment is favourable
CSIL benefits when trade and project activity create demand for marine, engineering and guarantee cover; when customers renew and premium pricing catches up with claims inflation; when valid reinsurance is available on economic terms; when fixed costs are spread over a larger premium base; and when investment markets deliver income without consuming liquidity. A favourable market is most valuable if underwriting is already disciplined.
When the environment turns adverse
The model weakens when regulatory permission or panel access limits premium generation, when one business class dominates, when collateral or reinsurance proves inadequate, when investment gains reverse, or when receivables fail to convert into cash. Because current premium volume is small relative to the cost base, even a moderate revenue interruption can push underwriting deep into loss.
How to read this company’s results
Start with gross written premium, then reconcile it to earned and net premium. Reserve releases can make net premium look stronger than current-year writing, while reinsurance changes the amount retained. Next, compare net claims, commission and acquisition cost, management expense and premium-deficiency provisions to derive the underwriting result. For CSIL, the underwriting result is the clearest test of whether the operating franchise works before investments.
Then separate investment income, realized and unrealized gains, other income and related-party interest from underwriting. Ask which items produced cash and which merely increased receivables or fair values. Read the cash-flow statement and movement in cash, investments, premium receivables, claims liabilities and unearned premium. A reported profit supported by weak cash and contested receivables deserves more caution than the same profit backed by premium collections.
Finally, read the auditor’s opinion before calculating return on equity or solvency. Track any reduction, recovery or independent support for the Rs330.235 million challenged receivable; look for impairment testing of subsidiary values; and reconcile capital raised with new shares, cash, investments and underwriting growth. Use unconsolidated and consolidated accounts consistently: subsidiary gains and losses can make group profit differ materially from the insurer-only result.
What to monitor next
The most useful indicators are: gross and net premium by class; the underwriting result before investment income; management expense as a percentage of net premium; collateral and reinsurance supporting guarantee exposures; outstanding guarantees; claims and premium-deficiency reserves; operating cash flow; cash and liquid investments; the status of the qualified audit matters; the use of rights proceeds; subsidiary impairment testing; and the gap between unconsolidated and consolidated profit.
The March 2026 quarterly loss makes the next interim accounts especially important. A durable improvement would require more than a rebound in investment income: readers should look for higher retained premium, better absorption of fixed expense, clean cash collection and clearer evidence that material assets are recoverable. That is the economic bridge between CSIL’s long history and a credible new growth phase.
Sources
Pakistan Stock Exchange — CSIL company profile, announcements and equity data
Crescent Star Insurance — official financial-statements archive
Crescent Star Insurance — official company overview
Crescent Star Insurance — official investor information
FY2025 annual report as distributed from the company’s PSX filing
FY2025 financial results as distributed from the company’s PSX filing
Final rights offer and subscription confirmation